Codeine

12th Annual MJBizCon Welcomes Thousands of Cannabis Professionals Who Dare to Grow, Innovate, and Inspire into 2024

Retrieved on: 
Wednesday, November 29, 2023

The 12th annual MJBizCon welcomed tens of thousands of cannabis professionals for the $34 billion industry's premier event.

Key Points: 
  • The 12th annual MJBizCon welcomed tens of thousands of cannabis professionals for the $34 billion industry's premier event.
  • MJBizCon is where the game changers, rule breakers, and disruptors unite to connect, innovate and leave their mark on the industry.
  • The annual "State of the Industry and Predictions for 2024'" opened the event this morning.
  • "With the possibility of rescheduling and tax policy change on the horizon, 2024 could be much more prosperous than 2023."

Ellen Mellody and Maria Brasco Wurmbach Join KCSA Strategic Communications in Senior Leadership Roles

Retrieved on: 
Wednesday, September 6, 2023

NEW YORK, Sept. 6, 2023 /PRNewswire/ -- KCSA Strategic Communications ("KCSA" or the "Firm"), a leading integrated communications firm, announced today an expansion of the senior leadership team within its cannabis and psychedelic practices. Ellen Mellody has joined the Firm as senior vice president of its Public Relations Team and Maria Brasco Wurmbach has joined as senior vice president of its Social Media Team. Both Ms. Mellody and Ms. Brasco Wurmbach previously served in senior leadership roles at MATTIO Communications ("MATTIO").

Key Points: 
  • NEW YORK, Sept. 6, 2023 /PRNewswire/ -- KCSA Strategic Communications ("KCSA" or the "Firm"), a leading integrated communications firm, announced today an expansion of the senior leadership team within its cannabis and psychedelic practices.
  • Ellen Mellody has joined the Firm as senior vice president of its Public Relations Team and Maria Brasco Wurmbach has joined as senior vice president of its Social Media Team.
  • Both Ms. Mellody and Ms. Brasco Wurmbach previously served in senior leadership roles at MATTIO Communications ("MATTIO").
  • "KCSA is bringing on the strongest talent and growing the best strategic communications, investor relations and digital and social media practices across the financial, healthcare, tech, cannabis and psychedelics industries.

Introducing Fentanyl Substance Test: A Life-Saving Solution to Combat Fentanyl Overdoses

Retrieved on: 
Thursday, June 29, 2023

LOS ANGELES, June 29, 2023 /PRNewswire-PRWeb/ -- "As the opioid crisis continues to claim countless lives, we recognized the urgent need for a reliable tool to identify the presence of fentanyl, one of the most dangerous substances contributing to fatal overdoses. Our Fentanyl Substance Test empowers individuals by providing a quick, safe, and accurate solution to detect fentanyl and potentially prevent tragic consequences," said Charles White, CEO of At Home Drug Tester.

Key Points: 
  • Our Fentanyl Substance Test empowers individuals by providing a quick, safe, and accurate solution to detect fentanyl and potentially prevent tragic consequences," said Charles White, CEO of At Home Drug Tester.
  • Key features of the Fentanyl Substance Test:
    Detects Fentanyl: Our Fentanyl Substance Test is specifically developed to detect the presence of fentanyl in powdered substances.
  • Introducing the Fentanyl Substance Test aligns with our commitment to combat the opioid crisis and prevent fentanyl-related overdoses.
  • To learn more about the Fentanyl Substance Test and our comprehensive range of at-home drug testing solutions, please visit our website at https://athomedrugtester.com/product/drugid-fentanyl .

'Nature's own Ozempic' or berberine is all over social media. But does it really help you lose weight?

Retrieved on: 
Friday, June 2, 2023

It’s the herbal preparation berberine.

Key Points: 
  • It’s the herbal preparation berberine.
  • Influencers have been enthusiastically claiming its success in helping them lose weight, with their posts viewed by millions.
  • Does it help people lose weight?

Why berberine? What is it anyway?

    • That includes the high-profile prescription medicine Ozempic, a diabetes drug that also leads to weight loss.
    • Berberine is a bitter tasting chemical extracted from the roots of plants, such as goldenseal and barberry.
    • Berberine extracts have been used in traditional medicines for disorders of the gut and to treat infections.

Is it the same as Ozempic?

    • Ozempic is the brand name of the drug semaglutide, which is used to treat people with type 2 diabetes.
    • More recently, Ozempic has been shown to be effective for weight loss in people who are overweight or obese.
    • Read more:
      Ozempic helps weight loss by making you feel full.

Does berberine help you lose weight?

    • The strongest evidence we have comes from two meta-analyses, types of studies that pool together and analyse the results of other studies.
    • These show that taking a 300-3,000mg berberine a day orally is associated with modest reductions in body mass index (BMI), waist circumference and body weight (around 3kg).
    • We also don’t yet have the data to say what happens when people stop taking berberine.
    • We don’t exactly know how berberine works to help people lose weight.

Is berberine safe?

    • Just because berberine is sold over the counter, doesn’t mean it’s safe.
    • Berberine is not recommended for people who are pregnant as it is thought it can cross the placenta and may harm the fetus.
    • Berberine can also interact with many other drugs and supplements.

So what do do?

    • However, before buying berberine, discuss it with your doctor or pharmacist to see if it will be safe for you, or if other medications might be more appropriate.
    • Associate Professor Tina Hinton has previously received funding from the Schizophrenia Research Institute (formerly Neuroscience Institute of Schizophrenia and Allied Disorders).

Global Opioids Market Report 2022: Featuring Purdue, Johnson & Johnson, Hikma Pharmaceuticals, Pfizer, Abbvie, Sanofi, Sun Pharmaceutical, Grunenthal & Merck - ResearchAndMarkets.com

Retrieved on: 
Wednesday, November 16, 2022

Emergence of non-addictive alternative products to opioids for pain-management leads to decline in the growth of opioid market. According to American Society of Anesthesiologists, there are several non-opioid medicines that are available over the counter--steroids and NSAIDs such as aspirin, ibuprofen, and acetaminophen among others. Furthermore, wide availability and low cost associated with these drugs contribute to increase in demand for such products during the forecast period. For instance, aspirin cost USD 10 for a pack of 30 tablets.

Key Points: 
  • The global opioids market size is expected to reach USD 25.33 billion by 2030, registering CAGR of 1.2% during the forecast period.
  • Growing use of opioids for the management of post-operative pain, caused due to surgeries, is expected to drive the market growth.
  • Emergence of non-addictive alternative products to opioids for pain-management leads to decline in the growth of opioid market.
  • The growth of the region can be attributed to increasing geriatric population which are susceptible to the chronic pain
    Chapter 4 Global Opioids Market - Segment Analysis, By Product, 2018 - 2030 (USD Million)
    Chapter 5 Global Opioids Market - Segment Analysis, by Application, 2018 - 2030 (USD Million)
    Chapter 6 Global Opioids Market - Segment Analysis, by Route of Administration, 2018 - 2030 (USD Million)
    Chapter 7 Global Opioids Market - Segment Analysis, by Distribution Channel, 2018 - 2030 (USD Million)
    Chapter 9 Global Opioids Market: Competitive Analysis

Global Opioid Use Disorder Market Report to 2031 - Featuring Alkermes, AstraZeneca, BioDelivery Sciences International and Camurus Among Others - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 10, 2022

Opioid usage disorder (OUD) is a chronic, relapsing brain disorder that is characterized by obsessive opioid seeking and use despite negative effects.

Key Points: 
  • Opioid usage disorder (OUD) is a chronic, relapsing brain disorder that is characterized by obsessive opioid seeking and use despite negative effects.
  • Opioid use disorder consists of an overpowering desire to use opioids, increased opioid tolerance, and withdrawal syndrome when discontinued.
  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the opioid use disorder market analysis from 2021 to 2031 to identify the prevailing opioid use disorder market opportunities.
  • The report includes the analysis of the regional as well as global opioid use disorder market trends, key players, market segments, application areas, and market growth strategies.

Epic Research: Only 5% of Overdose Patients Tested for Fentanyl, #1 Killer of Americans 18-45

Retrieved on: 
Tuesday, August 23, 2022

VERONA, Wis., Aug. 23, 2022 /PRNewswire/ -- Overdoses—often from substances laced with fentanyl— and other unintentional injuries are now the top cause of death for Americans aged 1 to 44, and fentanyl overdoses are the top cause of death in those 18 to 45. In 2020, there were more than 56,000 overdose deaths from fentanyl and fentanyl analogs, which accounted for over 82% of opioid-involved deaths that year. Unfortunately, patients experiencing an overdose are rarely screened for fentanyl or other synthetic opioids when they visit emergency departments (ED). Providers are focused on treating the patient's symptoms and often administer naloxone as a prophylactic in any suspected overdose to give the patient the best chance of survival rather than waiting for toxicology results. Most EDs complete limited toxicology testing on patients that present for an overdose, but those toxicology panels often don't include synthetic opioids, like fentanyl.

Key Points: 
  • Unfortunately, patients experiencing an overdose are rarely screened for fentanyl or other synthetic opioids when they visit emergency departments (ED).
  • Most EDs complete limited toxicology testing on patients that present for an overdose, but those toxicology panels often don't include synthetic opioids, like fentanyl.
  • Their findings, which Epic Research published this morning , include the following:
    Patients are tested for fentanyl during just 5% of overdose-related ED visits.
  • When patients are tested for fentanyl, the positivity rate exceeds 40%more than three times that of opiates like morphine, heroin, and codeine.

Outlook on the Opioids Global Market to 2027 - High Incidence of Chronic Pain in Adults and Demand for Strong Agonists are Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 22, 2022

The Global Opioids Market size is expected to reach $5.4 billion by 2027, rising at a market growth of 3.5% CAGR during the forecast period.

Key Points: 
  • The Global Opioids Market size is expected to reach $5.4 billion by 2027, rising at a market growth of 3.5% CAGR during the forecast period.
  • Opioids essentially serve as pain relievers since they are composed of substances that relax muscles and alleviate pain and stress.
  • Opioids are the most commonly prescribed pain relievers for people suffering from moderate to severe chronic pain.
  • Individuals diagnosed with terminal illnesses suffering from severe and chronic physical pain are the main recipient of these analgesics.

PatientMetRx® Launches Patient Opinion Mapping for Fast, Accurate and Actionable Insights

Retrieved on: 
Wednesday, June 1, 2022

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220601005958/en/
    PatientMetRx launches Patient Opinion Mapping for fast, accurate and actionable insights (Photo: Business Wire)
    Until now, healthcare brands and their creative agencies have relied upon manually extracting insights from patient reports on specific medicines a process which is time-consuming and costly.
  • However, using AI-based technology, the Patient Opinion Map can now provide PatientMetRx users with fast, accurate and actionable insights about a patients experience with a branded medicine.
  • These insights are aimed at giving advertising agencies a competitive edge when it comes to audience insights for winning and retaining healthcare clients.
  • The Patient Opinion Map works by aggregating patient opinions on individual medicines from socially sourced posts.

The Worldwide Opioids Industry is Expected to Reach $6 Billion by 2030 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 4, 2022

The global opioids market was valued at $4,412.48 million in 2020, and is projected to reach $6,060.17 million by 2030, registering a CAGR of 3.2% from 2021 to 2030.

Key Points: 
  • The global opioids market was valued at $4,412.48 million in 2020, and is projected to reach $6,060.17 million by 2030, registering a CAGR of 3.2% from 2021 to 2030.
  • Prescription opioids are primarily used to treat moderate to severe pain, while some opioids can be used to alleviate coughing and diarrhea.
  • The growth of the global opioids market is driven by alarming increase in incidence of orthopedic diseases & chronic pain.
  • Furthermore, rise in disposable income and surge in geriatric population are expected to propel the growth of the global opioids market.